Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$63.96 USD

63.96
24,069,834

+2.16 (3.50%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $64.03 +0.07 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Moderna Rallies on Encouraging Coronavirus Vaccine Study Data

by Zacks Equity Research

Moderna's (MRNA) coronavirus vaccine candidate achieves levels of antibodies similar or higher than those typically found in a patient who recovered from COVID-19 naturally.

Zacks Equity Research

Stock Market News for May 19, 2020

by Zacks Equity Research

Wall Street rebounded impressively on Monday buoyed by an encouraging early-stage clinical trial data for a potential coronavirus vaccine.

Ritujay Ghosh headshot

5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up

by Ritujay Ghosh

Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.

Nalak Das headshot

Major Indexes Defying "Sell in May" Adage: 5 Growth Picks

by Nalak Das

Half of this month is already over, yet Wall Street is in green defying the well-known financial-world adage "Sell in May and go away."

Madeleine Johnson headshot

Here's Why Moderna (MRNA) Stock is Jumping Today

by Madeleine Johnson

On Monday, shares of biotech Moderna Inc. (MRNA) soared over 26% in midday trading, and closed up XX% to $X.

Benjamin Rains headshot

Buy Nvidia & Alibaba Stock Before Earnings for Coronavirus Resilience?

by Benjamin Rains

We dive into Nvidia and Alibaba ahead of their quarterly earnings results that are due out this week to help investors decide if either stock might worth buying...

Neena Mishra headshot

Moderna Soars: Biotech ETFs in Focus

by Neena Mishra

Positive data on early-stage coronavirus vaccine trial sent Moderna shares surging.

David Borun headshot

Stocks Take a Breather, but Good Weekend News Promises a Boost

by David Borun

Positive comments from the Fed Chairman and promising vaccine trial results provide a chance for a meaningful rally.

Zacks Equity Research

Market Gains on Powell's Speech and Moderna's Vaccine

by Zacks Equity Research

Market Gains on Powell's Speech and Moderna's Vaccine.

Mark Vickery headshot

Moderna (MRNA) COVID-19 Vaccine Looks Promising

by Mark Vickery

This news comes sooner and more positive than analysts had been expecting, and shares are up 35% in early trading this Monday.